MX374517B - Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos. - Google Patents

Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.

Info

Publication number
MX374517B
MX374517B MX2016008639A MX2016008639A MX374517B MX 374517 B MX374517 B MX 374517B MX 2016008639 A MX2016008639 A MX 2016008639A MX 2016008639 A MX2016008639 A MX 2016008639A MX 374517 B MX374517 B MX 374517B
Authority
MX
Mexico
Prior art keywords
rsv
specific antibodies
respiratory syncytial
syncytial virus
functional parts
Prior art date
Application number
MX2016008639A
Other languages
English (en)
Spanish (es)
Other versions
MX2016008639A (es
Inventor
Andy Q Yuan
Bettina Richter
Nancy Ulbrandt
Nicole Kallewaard-Lelay
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2016008639A publication Critical patent/MX2016008639A/es
Publication of MX374517B publication Critical patent/MX374517B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2016008639A 2014-01-15 2015-01-14 Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos. MX374517B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15
PCT/US2015/011391 WO2015108967A2 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof

Publications (2)

Publication Number Publication Date
MX2016008639A MX2016008639A (es) 2017-02-15
MX374517B true MX374517B (es) 2025-03-06

Family

ID=53543612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008639A MX374517B (es) 2014-01-15 2015-01-14 Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.

Country Status (26)

Country Link
US (6) US20160340414A1 (https=)
EP (3) EP3741390A1 (https=)
JP (4) JP6836398B2 (https=)
KR (1) KR102188437B1 (https=)
CN (2) CN116355080A (https=)
AU (4) AU2015206570A1 (https=)
CA (1) CA2933200C (https=)
CY (2) CY1123425T1 (https=)
DK (1) DK3094353T3 (https=)
ES (1) ES2795727T3 (https=)
FI (1) FIC20230016I1 (https=)
FR (1) FR23C1016I1 (https=)
HR (1) HRP20200607T1 (https=)
HU (2) HUE048855T2 (https=)
LT (2) LT3094353T (https=)
LU (1) LUC00305I2 (https=)
MX (1) MX374517B (https=)
NL (1) NL301228I2 (https=)
NO (1) NO2023016I1 (https=)
PL (1) PL3094353T3 (https=)
PT (1) PT3094353T (https=)
RS (1) RS60387B1 (https=)
SI (1) SI3094353T1 (https=)
SM (1) SMT202000282T1 (https=)
TW (1) TWI705974B (https=)
WO (1) WO2015108967A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
ES2795727T3 (es) 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20200140799A (ko) * 2018-01-31 2020-12-16 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
CA3229901A1 (en) 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
JP2010534057A (ja) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
US9273118B2 (en) * 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2486053B1 (en) * 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
BR112012031638B1 (pt) * 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
CA2867444C (en) * 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
US20150158942A1 (en) * 2012-05-22 2015-06-11 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma
CA2900110A1 (en) 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
ES2795727T3 (es) * 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Also Published As

Publication number Publication date
EP3094353A4 (en) 2017-09-06
NO2023016I1 (no) 2023-04-25
CY2023011I1 (el) 2023-11-15
JP2025063143A (ja) 2025-04-15
US11661449B2 (en) 2023-05-30
US12173050B2 (en) 2024-12-24
CN116355080A (zh) 2023-06-30
ES2795727T3 (es) 2020-11-24
US20220098285A1 (en) 2022-03-31
PT3094353T (pt) 2020-06-08
WO2015108967A3 (en) 2015-09-03
CA2933200A1 (en) 2015-07-23
US20250179153A1 (en) 2025-06-05
FR23C1016I1 (fr) 2023-06-23
AU2015206570A1 (en) 2016-07-14
HK1225992A1 (en) 2017-09-22
US20160340414A1 (en) 2016-11-24
TWI705974B (zh) 2020-10-01
AU2021204339B2 (en) 2024-11-14
LUC00305I2 (https=) 2025-09-22
CY2023011I2 (el) 2023-11-15
EP3094353A2 (en) 2016-11-23
AU2020203831A1 (en) 2020-07-02
CA2933200C (en) 2025-05-06
EP3741390A1 (en) 2020-11-25
CY1123425T1 (el) 2021-12-31
FIC20230016I1 (fi) 2023-04-26
RS60387B1 (sr) 2020-07-31
US20190106482A1 (en) 2019-04-11
EP3094353B1 (en) 2020-04-01
BR112016015044A2 (pt) 2017-09-19
SMT202000282T1 (it) 2020-07-08
JP2017504321A (ja) 2017-02-09
JP2020103293A (ja) 2020-07-09
HRP20200607T1 (hr) 2020-07-10
ES2795727T9 (en) 2026-01-21
PL3094353T3 (pl) 2020-09-07
BR112016015044A8 (pt) 2023-04-11
HUE048855T2 (hu) 2020-08-28
AU2025201056A1 (en) 2025-03-06
JP2023052693A (ja) 2023-04-11
NL301228I1 (https=) 2023-05-03
LT3094353T (lt) 2020-08-10
HUS2300019I1 (hu) 2023-05-28
EP4353316A2 (en) 2024-04-17
WO2015108967A2 (en) 2015-07-23
AU2021204339A1 (en) 2021-07-22
WO2015108967A8 (en) 2015-10-01
MX2016008639A (es) 2017-02-15
TW201612191A (en) 2016-04-01
RU2016133247A3 (https=) 2019-01-16
SI3094353T1 (sl) 2020-07-31
DK3094353T3 (da) 2020-06-02
EP4353316A3 (en) 2024-08-21
JP6836398B2 (ja) 2021-03-03
LTC3094353I2 (https=) 2025-07-10
US11186628B2 (en) 2021-11-30
NL301228I2 (nl) 2023-09-13
CN105916520A (zh) 2016-08-31
RU2016133247A (ru) 2018-02-20
KR102188437B1 (ko) 2020-12-08
LTPA2023514I1 (https=) 2023-05-25
KR20160104018A (ko) 2016-09-02
US20230365660A1 (en) 2023-11-16
US10689437B2 (en) 2020-06-23
US20200331989A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MX374517B (es) Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.
EA201890441A1 (ru) Моноклональные антитела против bcma
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3368562T3 (da) Antistof, der neutraliserer humant respiratorisk syncytialvirus
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
LT3110440T (lt) Anti-cd38 antikūnai, skirti ūminės limfoblastinės leukemijos gydymui
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
DK3142785T3 (da) Fremgangsmåde til fremstilling af alkenoler og anvendelse deraf til fremstilling af 1,3-butadien
MX2023006415A (es) Anticuerpos, usos y metodos.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
CO2017010143A2 (es) Procesos para preparar fluorocetólidos
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler
EA201792527A1 (ru) Лечение зуда
EA201691203A1 (ru) Твёрдые формы тенофовира
MX382631B (es) Proceso para la preparacion de derivados dihidroisoxazol.
LT3493849T (lt) N,n-bis-2-merkaptoetilizoftalamido naujas panaudojimas
MX380240B (es) Preparación de piperidin-4-carbotioamida.
ES2722574R1 (es) Proceso para la preparación de 9beta,10alfa-progesterona (retroprogesterona)
UY36284A (es) Método para la preparación de imidazopiridazinas sustituidas

Legal Events

Date Code Title Description
FG Grant or registration